<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01432561</url>
  </required_header>
  <id_info>
    <org_study_id>111011</org_study_id>
    <nct_id>NCT01432561</nct_id>
  </id_info>
  <brief_title>Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™</brief_title>
  <official_title>Food-Effect on Bioavailability of Cystagon™ in Normal, Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Raptor Pharmaceuticals Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to meet FDA standards of safety and efficacy reporting for most new drugs,
      food-effect bioavailability (the impact that the presence of food in the digestive tract has
      on the rate and extent at which a drug is absorbed into the bloodstream and delivered to the
      site of action) must be collected. Cystagon™ is an FDA approved drug for the treatment of the
      rare disease cystinosis that became available in 1994, but there is inadequate knowledge of
      the food-effect on this drug's bioavailability. This study aims to investigate how food
      affects the absorption of Cystagon™ into the bloodstream of normal healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cysteamine Absorption: Area Under the Plasma Concentration Curve (AUC)</measure>
    <time_frame>0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180 minutes, and 3.5, 4, 4.5, 5, 6 hours post‐dose</time_frame>
    <description>Subjects were randomized to one of two possible treatment sequences using block randomization: Sequence 1 - fasted, high-fat, high-protein or Sequence 2 - high-protein, high-fat, fasted. Sequence assignment determined the treatment condition corresponding to Period I, II &amp; III visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Cysteamine Concentration (Cmax)</measure>
    <time_frame>0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180 minutes, and 3.5, 4, 4.5, 5, 6 hours post‐dose</time_frame>
    <description>Subjects were randomized to one of two possible treatment sequences using block randomization: Sequence 1 - fasted, high-fat, high-protein or Sequence 2 - high-protein, high-fat, fasted. Sequence assignment determined the treatment condition corresponding to Period I, II &amp; III visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Peak Plasma Cysteamine Concentration (Tmax)</measure>
    <time_frame>0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180 minutes, and 3.5, 4, 4.5, 5, 6 hours post‐dose</time_frame>
    <description>Subjects were randomized to one of two possible treatment sequences using block randomization: Sequence 1 - fasted, high-fat, high-protein or Sequence 2 - high-protein, high-fat, fasted. Sequence assignment determined the treatment condition corresponding to Period I, II &amp; III visits.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Cystinosis</condition>
  <condition>Nephropathic Cystinosis</condition>
  <arm_group>
    <arm_group_label>Cysteamine bitartrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cysteamine bitartrate, 500mg once a day, three days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cysteamine bitartrate</intervention_name>
    <description>500 mg total, single dose taken orally on visits 2, 3 &amp; 4 which must occur within a 14 day period.</description>
    <arm_group_label>Cysteamine bitartrate</arm_group_label>
    <other_name>Cystagon</other_name>
    <other_name>Cysteamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, smoker (no more than 25 cigarettes daily) or non-smoker, 18 years of
             age and older, with BMI &gt; 18 and &lt; 30.0.

          2. Females of childbearing potential who are sexually active must be willing to use two
             forms of contraceptive methods throughout the study and for 14days after the last
             study drug administration.

          3. Minimum weight of 50 kg.

          4. Good health, defined as not having history of any chronic illness and not requiring
             any regular medication/therapy.

          5. Must swallow tablets on a regular basis.

        Exclusion Criteria:

          1. Evidence of Helicobacter pylori infection, presently, or within the last year.

          2. Subjects with known hypersensitivity to cysteamine.

          3. History, currently or within the past 3 months, of the following conditions:

               -  Pancreatitis

               -  Inflammatory bowel disease

               -  Malabsorption

               -  Severe liver disease

               -  Unstable heart disease, e.g., myocardial infarction, heart failure, arrhythmias.

               -  Unstable diabetes mellitus

               -  Any bleeding disorder.

               -  Zollinger-Ellison syndrome

               -  Malignant disease

          4. Subjects whom may be pregnant or have health issues that make it unsafe for them
             participate, or whose concomitant medical problems preclude them from committing to
             the study schedule.

          5. Use of an investigational drug within 30 days (or 90 days for biologics) prior to
             dosing.

          6. Use of prescription medication within 14 days prior to the first dosing;

          7. Use over-the-counter products including natural health products (e.g. food supplements
             and herbal supplements) within 7 days prior to the first dosing.

          8. Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding
             volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than
             499 mL within 56 days prior to dosing.

          9. Hemoglobin &lt;13.5 g/dL (males) and &lt;12.0 g/dL (females) and hematocrit &lt;41.0% (males)
             and &lt;36.0% (females) at screening.

         10. Breast-feeding subject.

         11. Immunization with a live attenuated vaccine 1 month prior to dosing or planned
             vaccination during the course of the study.

         12. Presence of fever (body temperature &gt;37.6°C) (e.g. a fever associated with a
             symptomatic viral or bacterial infection) within 2 weeks prior to dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ranjan Dohil, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego Center for Clinical Research Services (CCR)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med. 2002 Jul 11;347(2):111-21. Review.</citation>
    <PMID>12110740</PMID>
  </reference>
  <reference>
    <citation>Gahl WA, Reed GF, Thoene JG, Schulman JD, Rizzo WB, Jonas AJ, Denman DW, Schlesselman JJ, Corden BJ, Schneider JA. Cysteamine therapy for children with nephropathic cystinosis. N Engl J Med. 1987 Apr 16;316(16):971-7.</citation>
    <PMID>3550461</PMID>
  </reference>
  <reference>
    <citation>Markello TC, Bernardini IM, Gahl WA. Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med. 1993 Apr 22;328(16):1157-62.</citation>
    <PMID>8455682</PMID>
  </reference>
  <reference>
    <citation>Smolin LA, Clark KF, Thoene JG, Gahl WA, Schneider JA. A comparison of the effectiveness of cysteamine and phosphocysteamine in elevating plasma cysteamine concentration and decreasing leukocyte free cystine in nephropathic cystinosis. Pediatr Res. 1988 Jun;23(6):616-20.</citation>
    <PMID>3393396</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2011</study_first_submitted>
  <study_first_submitted_qc>September 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2011</study_first_posted>
  <results_first_submitted>July 3, 2013</results_first_submitted>
  <results_first_submitted_qc>September 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 9, 2013</results_first_posted>
  <last_update_submitted>September 23, 2013</last_update_submitted>
  <last_update_submitted_qc>September 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Ranjan Dohil</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lysosomal Storage Diseases</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Metabolism, Inborn Errors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystinosis</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cysteamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: 09/19/2011 - 11/21/2012 Recruitment Locations: medical centers</recruitment_details>
      <pre_assignment_details>Screening for liver function and H pylori infection and brief medical history in order to determine if all inclusion and exclusion criteria were met. One enrollee met all inclusion criteria but clinical lab test revealed presence of H Pylori, an exclusion factor. Two enrollees withdrew from the trial prior to assignment due to scheduling conflicts.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cysteamine Bitartrate</title>
          <description>Cysteamine bitartrate, 500mg once a day, three days.
Cysteamine bitartrate : 500 mg total, single dose taken orally on visits 2, 3 &amp; 4 which must occur within a 14 day period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cysteamine Bitartrate</title>
          <description>Cysteamine bitartrate, 500mg once a day, three days.
Cysteamine bitartrate : 500 mg total, single dose taken orally on visits 2, 3 &amp; 4 which must occur within a 14 day period.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.9" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cysteamine Absorption: Area Under the Plasma Concentration Curve (AUC)</title>
        <description>Subjects were randomized to one of two possible treatment sequences using block randomization: Sequence 1 - fasted, high-fat, high-protein or Sequence 2 - high-protein, high-fat, fasted. Sequence assignment determined the treatment condition corresponding to Period I, II &amp; III visits.</description>
        <time_frame>0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180 minutes, and 3.5, 4, 4.5, 5, 6 hours post‐dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cysteamine Bitartrate</title>
            <description>Cysteamine bitartrate : 500 mg total, single dose taken orally on visits 2, 3 &amp; 4</description>
          </group>
        </group_list>
        <measure>
          <title>Cysteamine Absorption: Area Under the Plasma Concentration Curve (AUC)</title>
          <description>Subjects were randomized to one of two possible treatment sequences using block randomization: Sequence 1 - fasted, high-fat, high-protein or Sequence 2 - high-protein, high-fat, fasted. Sequence assignment determined the treatment condition corresponding to Period I, II &amp; III visits.</description>
          <units>min*uM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fasted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3618" spread="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fed High-Fat/Calorie</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2799" spread="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fed High-Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2457" spread="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>High-fat/calorie compared to fasted condition</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.04</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>High-protein compared to fasted condition</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.005</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Plasma Cysteamine Concentration (Cmax)</title>
        <description>Subjects were randomized to one of two possible treatment sequences using block randomization: Sequence 1 - fasted, high-fat, high-protein or Sequence 2 - high-protein, high-fat, fasted. Sequence assignment determined the treatment condition corresponding to Period I, II &amp; III visits.</description>
        <time_frame>0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180 minutes, and 3.5, 4, 4.5, 5, 6 hours post‐dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cysteamine Bitartrate</title>
            <description>Cysteamine bitartrate : 500 mg total, single dose taken orally on visits 2, 3 &amp; 4</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Cysteamine Concentration (Cmax)</title>
          <description>Subjects were randomized to one of two possible treatment sequences using block randomization: Sequence 1 - fasted, high-fat, high-protein or Sequence 2 - high-protein, high-fat, fasted. Sequence assignment determined the treatment condition corresponding to Period I, II &amp; III visits.</description>
          <units>uM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fasted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fed High-Fat/Calorie</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fed High-Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>High-fat/calorie compared to fasted condition</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.16</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>High-protein compared to fasted condition</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.036</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Peak Plasma Cysteamine Concentration (Tmax)</title>
        <description>Subjects were randomized to one of two possible treatment sequences using block randomization: Sequence 1 - fasted, high-fat, high-protein or Sequence 2 - high-protein, high-fat, fasted. Sequence assignment determined the treatment condition corresponding to Period I, II &amp; III visits.</description>
        <time_frame>0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180 minutes, and 3.5, 4, 4.5, 5, 6 hours post‐dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cysteamine Bitartrate</title>
            <description>Cysteamine bitartrate : 500 mg total, single dose taken orally on visits 2, 3 &amp; 4</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Plasma Cysteamine Concentration (Tmax)</title>
          <description>Subjects were randomized to one of two possible treatment sequences using block randomization: Sequence 1 - fasted, high-fat, high-protein or Sequence 2 - high-protein, high-fat, fasted. Sequence assignment determined the treatment condition corresponding to Period I, II &amp; III visits.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fasted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.2" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fed High-Fat/Calorie</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.9" spread="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fed High-Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Fed high-fat/calorie compared to fasted condition.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.30</p_value>
            <method>Non-parametric Hodges-Lehmann method</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>High-protein compared to fasted condition</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.05</p_value>
            <method>Non-parametric Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data collected beginning date of enrollment and continuing to study withdrawal/termination or up to 7 days after last study visit, as applicable. Total duration of data collection varied among the subjects based on clinic scheduling.</time_frame>
      <desc>At study visits, subjects queried at specified intervals before and after drug administration (t=0, 30, 60, 90, 120 and 180 minutes) via a brief survey. Spontaneous A.E. observed and noted also.
Between study visits, A.E.'s as reported by participants at the beginning of each study visit and 7 days after the final study visit were noted .</desc>
      <group_list>
        <group group_id="E1">
          <title>Cysteamine Bitartrate</title>
          <description>Cysteamine bitartrate, 500mg once a day, three days.
Cysteamine bitartrate : 500 mg total, single dose taken orally on visits 2, 3 &amp; 4 which must occur within a 14 day period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ranjan Dohil, P.I.</name_or_title>
      <organization>University of California San Diego</organization>
      <phone>619-471-9554</phone>
      <email>rdohil@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

